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Inflammatory Muscle Diseases
To the Editor: In the review article on inflam-
matory muscle diseases, Dalakas (April 30 issue)1 
outlines four major subtypes. In 1998, Gherardi 
et al. described a new but underrecognized clini-
cal variant, called macrophagic myofasciitis,2 a 
condition that presents as diffuse myalgias of 
variable intensity associated with chronic fa-
tigue. Myalgia predominantly affects the lower 
limbs and is often aggravated by exercise. It is 
associated with arthralgias in 50 to 60% of pa-
tients, as well as fever in 30% of patients.3 Re-
sults on electromyography may be myopathic, 
and creatine kinase levels may be elevated in up 
to 50% of patients.4 This disease is associated 
with intramuscular injection of aluminum hy-
droxide, which is used as an adjuvant in several 
vaccines (hepatitis A and B).3 Muscle biopsy, in-
cluding the fascia, at the site of the immuniza-
tion reveals a pathognomonic focal macrophage 
infiltration with intracytoplasmic crystalline in-
clusions corresponding to aluminum deposits.2 
This picture is part of the inflammatory autoim-
mune syndrome induced by adjuvants.5
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To the Editor: We are concerned about the 
statement in the review article by Dalakas that 
the long-term outcome of inflammatory myop-
athies has improved, with “a 10-year survival rate 
of more than 90%.” In 2006, Airio et al. reported 
a 10-year survival rate of 55% among patients 
with polymyositis and 53% among those with 
dermatomyositis.1 In 2012, Schiopu et al. report-
ed a 10-year survival rate of 62% in inflammatory 
myopathies.2 In 2014, Aggarwal et el. reported a 
10-year survival rate of 70% among patients with 
a positive autoantibody response to histidyl-trans-
fer RNA synthetase (Jo-1) and 50% among pa-
tients with a negative response.3 Taborda et al. 
reported a 10-year survival rate of more than 90% 
in the United Kingdom,4 as cited by Dalakas. In 
general, the mean 10-year survival rate among 
patients with inflammatory myopathies from the 
cited four studies is approximately 69%, a rate 
that might be affected by ethnic group, serologic 
presentation, and disease severity. Moreover, in 
patients in whom the myopathy is associated 
with cancer, the prognosis is even worse. Though 
diagnostic methods and therapies have improved, 
we should avoid being overly optimistic about the 
prognosis.
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The author replies: Young et al. refer to a mac-
rophage-mediated inflammatory disorder that 
affects muscle fascia but not myofibers that are 
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remote from the macrophagic infiltrates.1 In con-
trast to inflammatory muscle diseases, macro-
phagic myofasciitis presents with myalgia and 
chronic fatigue but not muscle weakness, has fo-
cal histopathological features that are limited to 
the fascia and occasionally perifascicular fibers 
of deltoid muscles in sites of previous vaccina-
tions, and is predominantly, if not exclusively, seen 
in France, where the deltoid muscles (used for 
vaccinations) are routinely preferred for diagnos-
tic biopsies.1 Macrophagic myofasciitis is a seem-
ingly toxic fasciitis, not a primary inflammatory 
muscle disease, that is linked to aluminum-con-
taining substrates in some vaccines, similar to 
the eosinophilia–myalgia syndrome caused by 
adulterated L-tryptophan.2 Whether these focal 
fascial macrophagic collections are incidental 
reactions to the injected vaccines or trigger the 
reported systemic symptoms of fatigue, myalgia, 
and cognitive dysfunction remains unclear. The 
proposed hypothesis that there is an autoimmune 
or inflammatory syndrome induced by adjuvants 
is beyond the scope of my review.
Chen et al. refer to survival rates in four dif-
ferent studies with heterogeneous diagnostic 
criteria that have not been adjusted for systemic 
conditions or systematically applied immuno-
therapies. Thus, lumping the rates into one group 
to obtain a mean survival rate is not appropriate. 
The study they cite by Airio et al. refers to pa-
tients who were evaluated 30 to 46 years ago, 
whereas the study they cite by Aggarwal et al. 
was limited to patients with Jo-1 antibodies who 
often have interstitial lung disease. The reference 
that I cited (in spite of its limitations) is more 
representative because it includes patients from 
one center in which practitioners were experi-
enced in modern immunotherapies. Improved 
supportive care and the application of new thera-
pies, such as intravenous immune globulin and 
rituximab, probably account for improved rates 
of survival. A life expectancy of 81 years was 
reportedly normal even for patients with inclu-
sion-body myositis, the most disabling of the 
myositis subtypes.3 The numbers of patients who 
were included in these studies are arguably small, 
and we need better survival studies that take 
into consideration various factors including cor-
rect diagnosis (ensuring specific rates for each 
disease subtype), the patient’s age at onset, the 
presence of cancer or pulmonary involvement, 
the time from the initiation of therapy, disease 
severity, and the judicious use of immunothera-
pies and good supportive care. I hope that the 
data in my review article will lead to increased 
diagnostic accuracy, early initiation of more effec-
tive immunotherapies, and higher survival rates.
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